ReproCELL, Inc.

BENGALURU, Karnataka, India I December 01, 2024 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA) has approved YESINTEK™ (Ustekinumab-kfce), a biosimilar to the reference product, Stelara® (Ustekinumab). YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis. Biocon Biologics Ltd had previously notified the Stock Exchange on Feb 29, 2024, that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize YESINTEK™ in the United States of America no later than on February 22, 2025, upon approval from the U.S. FDA. SOURCE: Biocon Biologics

DUBLIN--( BUSINESS WIRE )--The "3D Cell Culture - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. The global market for 3D Cell Culture is estimated at US$1.9 billion in 2024 and is expected to record a CAGR of 14.5% during the 2024-2030 analysis period and stand at a projected US$4.3 billion by 2030. This global report on 3D Cell Culture analyzes the market based on type, application, and end users. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing. 3D cell culture involves cultivating and interacting cells in three dimensions to mimic natural tissue environments, improving research in drug screening, tissue engineering, and more. This method addresses 2D culture limitations by encouraging cell differentiation and organization while enabling precise control of environmental conditions. 3D cell cultures can be scaffold-based or scaffold-free, using various methods to create spheroids and organoids. Spheroids are multi-layered cell aggregates, while organoids are miniaturized versions of organs with self-differentiation capabilities. The 3D cell culture market is driven by advancements in regenerative medicine, enabling the creation of tissue structures that mimic natural environments and support deeper investigation into tissue regeneration and engineering. The adoption of 3D cell culture technologies is increasing for more accurate drug discovery, disease modeling, and personalized medicine, driven by the rising prevalence of chronic diseases like cancer and diabetes. Investments from government and NGOs combined with a move towards ethical research practices that minimize animal testing, further drive 3D cell culture market growth. Technological innovations such as 3D printing and microfluidics enhance model realism, while regulatory support from bodies like the FDA and EMA promotes their use in drug efficacy and toxicity studies. 3D Cell Culture Regional Market Analysis In 2024, North America dominates the global 3D cell culture market with a 42.5% share, driven by its advanced healthcare infrastructure, strong research institutions, and government funding for innovative cell culture technologies. This dominance is expected to continue, supported by high R&D spending and a robust pharmaceutical sector. Conversely, the Asia-Pacific region is projected to experience the highest growth, with a CAGR of 16.4% from 2024 to 2030. This rapid expansion is fueled by increasing investments in biotechnology, high disease burden, and a surge in demand for advanced 3D culture models for drug discovery and personalized medicine. The region's growing pharmaceutical and biotech sectors, along with supportive government initiatives, contribute significantly to its accelerated market growth. 3D Cell Culture Market Analysis by Product Type In 2024, the scaffold-based segment dominated the market, holding a 48.3% share due to its applications in tissue engineering, regenerative medicine, and breakthroughs in scaffold materials, and increased research funding. Scaffold-based cultures mimic native tissues better, driving the market demand for drug discovery and toxicity testing. Meanwhile, the scaffold-free segment is expected to grow at the fastest CAGR of 16.6% from 2024 to 2030, driven by the need for personalized medicine, advancements in 3D culture models, and high demand from biopharmaceutical companies. The ease of use and scalability of scaffold-free systems further boost their adoption. 3D Cell Culture Market Analysis by Application In 2024, the stem cell research & tissue engineering segment led the market with a 30.9% share. This dominance is driven by increasing demand for biopharmaceuticals, including cell and gene therapies, alongside supportive government regulations and funding boosts. However, the cancer research segment is poised to grow the fastest, with a projected CAGR of 16.2% from 2024 to 2030. This growth is fuelled by the rising cancer prevalence and the advantages of 3D culture models, which offer better manipulation of cell proliferation, morphology, and imaging capabilities. 3D Cell Culture Market Analysis by End-User In 2024, Biotechnology and Pharmaceutical Companies led the 3D cell culture market with a 45.2% share, driven by the need for advanced cell models in drug discovery and personalized medicine. This dominance is expected to continue due to the benefits of 3D models, such as realistic cell interactions and optimal nutrient gradients. Conversely, the Academic & Research Institutes segment is projected to grow at a CAGR of 15.6% from 2024 to 2030, fuelled by technology advancements, increased research activities, and collaborations with industry. The segment's growth reflects the rising adoption of 3D cell culture in research settings. Key Attributes: Report Attribute Details No. of Pages 265 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.9 Billion Forecasted Market Value (USD) by 2030 $4.3 Billion Compound Annual Growth Rate 14.5% Regions Covered Global 3D Cell Culture Key Global Players 3D Biotek, LLC Advanced Biomatrix, Inc. Avantor Inc. Becton Dickinson and Company CN Bio Innovations Ltd Corning Inc. Emulate Inc. Greiner Bio One International GmbH InSphero AG Lonza Group AG Merck KGaA Mimetas B.V. Nanofiber Solutions PromoCell GmbH REPROCELL Inc. Sartorius AG Synthecon Inc Tecan Trading AG Thermo Fisher Scientific Inc. 3D Cell Culture Market Report Scope Key Metrics Historical Period: 2021-2023 Base Year: 2023 Forecast Period: 2024-2030 Units: Value market in US$ Companies Mentioned: 15+ 3D Cell Culture Market by Geographic Region North America (The United States, Canada, and Mexico) Europe (Germany, France, The United Kingdom, Spain, Italy, and Rest of Europe) Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific) South America (Brazil, Argentina, and Rest of South America) Rest of World 3D Cell Culture Market by Type Scaffold-based Scaffold-free Microfluidics-based Bioreactors 3D Cell Culture Market by Application Cancer Research Stem Cell Research & Tissue Engineering Drug Development Other Applications (Including Toxicology, Regenerative Medicine, Organ-on-a-Chip, Neurobiology, and Immunology) 3D Cell Culture Market by End User Biotechnology and Pharmaceutical Companies Academic & Research Institutes Hospitals and Diagnostics Other End Users (Including Chemicals, Agrochemicals, Cosmetics, and Food & Beverages) For more information about this report visit https://www.researchandmarkets.com/r/hc9ucb About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN--( BUSINESS WIRE )--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering. This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development. It covers the current status of iPSC research, biomedical applications, manufacturing technologies, patents, and funding events, as well as all known trials for the development of iPSC-derived cell therapeutics worldwide. Importantly, it profiles leading market competitors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World). It also presents total market size figures with projected growth rates through 2030. Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases. Today, methods of commercializing induced pluripotent stem cells (iPSCs) include: Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease. Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models "in a dish". Drug Development and Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery. Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine. Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of iPSCs or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells. Tissue Engineering: iPSCs can be seeded onto scaffolds made from biocompatible materials. These scaffolds mimic the structure and properties of the target tissue and can provide a supportive environment for cell growth and differentiation. Organoid Production: iPS cells can be coaxed to self-organize into 3D structures called organoids, which mimic the structure and function of organs. Organoids can be used for studying organ development, modeling diseases, and testing drugs. Gene Editing: iPS cells can be genetically modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic changes. These edited iPS cells can then be differentiated into the desired cell type for transplantation or disease modeling. Research Tools: iPSCs and iPSC-derived cell types are being widely used within a diverse range of basic and applied research applications. Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors. Cultured Meat Production: iPSCs are being utilized in clean meat production by serving as the cellular foundation for the creation of lab-grown meat. 3D Bioprinting: iPSCs can be directed to differentiate into cell types of interest, such as skin, heart, or liver cells, which are then incorporated into bioinks. Wildlife Conservation and De-extinction Projects: iPSCs are being used in wildlife conservation and de-extinction projects. For example, Colossal Biosciences is using iPSC technology in an effort to achieve woolly mammoth de-extinction. Key Topics Covered: 1. REPORT OVERVIEW 2. INTRODUCTION 3. CURRENT STATUS OF IPSC INDUSTRY 3.1 Progress made in Autologous Cell Therapy using iPSCs 3.2 Allogeneic iPSC-based Cell Therapies 3.3 Share of iPSC-based Research within the Overall Stem Cell Industry 3.4 Major Focus Areas of iPSC Companies 3.5 Commercially Available iPSC-derived Cell Types 3.6 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays 3.7 iPSC-derived Cell Types used in Clinical Trials 3.8 Currently Available iPSC Technologies Nucleofector Technology Opti-ox Technology MOGRIFY Technology Transcription Factor-based iPSC Differentiation Technology Flowfect Technology Technology for Mass Production of Platelets SynFire Technology 4. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 5. RESEARCH PUBLICATIONS ON IPSCS 6. IPSC: PATENT LANDSCAPE ANALYSIS 6.1 iPSC Patent Applications by Jurisdiction 6.2 iPSC Patent Applicants 6.3 Inventors of iPSC Patents 6.4 iPSC Patent Owners 6.5 Legal Status of iPSC Patents 7. IPSC: CLINICAL TRIAL LANDSCAPE 7.1 Number of iPSC Clinical Trials 7.2 Recruitment Status of iPSC Clinical Trials 7.3 iPSC Clinical Trials Study Designs 7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials 7.5 iPSC-based Trials by Phase of Study 7.6 iPSC Clinical Trials by Funder Type 7.7 Geographic Distribution of iPSC-based Clinical Trials 7.8 Promising iPSC Product Candidates CYP-001, CYP-004 & CYP-006 from Cynata Therapeutics BioVAT-HF from Repairon GmbH HS-001 from Heartseed CNTY-101 from Century Therapeutics FT-576 & FT-819 from Fate Therapeutics RPE from National Eye Institute QN-019a from Qihan Biotech iPSC-CL from Heartworks, Inc. 7.9 Companies having Preclinical iPSC Assets Aspen Neuroscience Ryne Biotech Bluerock Therapeutics Vita Therapeutics Hopstem Biotechnology Res Nova Bio, Inc. Cytovia Therapeutics Hebecell Corporation Sana Biotechnology SCG Cell Therapy Pte Cytomed Shoreline Biosciences Neukio Biotherapeutics Exacis Biotherapeutics CellOrigin Biotech 8. M&A, COLLABORATIONS & FUNDING ACTIVITIES IN IPSC SECTOR 8.1 Mergers and Acquisitions (M&A) Sector Century Therapeutics & Clade Therapeutics Evotech & Rigenerand Fujifilm Corporation & Atara Biotherapeutics Catalent & RheinCell Therapeutics Axol Biosciences & Censo Biotechnologies Bayer AG & Bluerock Therapeutics Pluriomix & Axiogenesis 8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector Shinobi Therapeutics & Panasonic SCG Cell Therapy and A*STAR Charles River Laboratories & Pluristyx, Inc. Pluristyx, Inc. & National Resilience, Inc. University of Texas & GeneCure Heartseed, Inc. & Undisclosed Biotech Bluerock Therapeutics & Bit.bio Applied Stem Cell, Inc. & CIRM Resolution Therapeutics & OmniaBio, Inc. REPROCELL, Inc. & CIRM REPROCELL, Inc. & BioBridge Global Elevate Bio & CIRM Evotec & Sernova Evotec & Almiral Quell Therapeutics & Cellistic MDimmune & YiPSCELL Edigene & Neukio Biotherapeutics Matricelf & Ramot Evotec & Boehringer Ingelheim Pluristyx, Pancella & Implant Therapeutics Century Therapeutics & Bristol Myers Squibb Fujifilm Cellular Dynamics & Pheno Vista Biosciences Metrion Biosciences & Bioqube Ventures Cytovia Therapeutics & Cellectis Exacis Biotherapeutics & CCRM Cynata Therapeutics & Fujifilm Corporation Bone Therapeutics & Implant Therapeutics REPROCELL & TEXCELL Jacobio & Herbecell NeuCyte & KIF1A.ORG Kite & Shoreline Biosciences Neuropath Therapeutics & Hopstem Biotechnology Allele Biotech & Cellatoz Bluerock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics Newcells & Takeda Biocentriq & Kytopen Fujifilm Cellular Dynamics & Sana Biotechnology Evotec & Medical Center Hamburg-Eppdorf (UKE) NeuCyte & Seaver Autism Center for Research and Treatment Cytovia Therapeutics & National Cancer Institute Mogrify & MRC Laboratory of Molecular Biology 8.3 Venture Capital Funding in iPSC Sector Asgard Therapeutics Kenai Therapeutics Pluristyx Fujifilm Cellular Dynamics Mogrify Ltd. Heartseed, Inc. Elevate Bio Aspen Neurosciences Axol Biosciences Thyas, Co. Ltd Synthego Cellino Biotech, Inc Curi Bio Ncardia Evotec SE bit.bio Clade Therapeutics Shoreline Biosciences Kytopen Cytovia Therapeutics & CytoLynx TreeFrog Therapeutics HebeCell Corporation Neukio Biotherapeutics Stemson Therapeutics Vita Therapeutics Century Therapeutics Heartseed Mogrify Metrion Biosciences Elevate Bio Vita Therapeutics 9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 9.1 OSKM Cocktail 9.2 Pluripotency-Associated Transcription Factors and their Functions 9.3 Delivery of Reprogramming Factors 9.3.1 Integrating Systems 9.3.2 Non-Integrative Delivery Systems 9.3.3 Comparison of Delivery Methods 9.4 Genome Editing Technologies in iPSC Generation 9.5 Available iPSC Lines and their applications 10. HUMAN IPSC BANKING 10.1 Major Biobanks Storing iPSCs & iPSC Lines 10.1.1 RIKEN 10.1.2 WiCell 10.1.3 Fujifilm Cellular Dynamics, Inc. 10.1.4 Sampled 10.1.5 Coriell Institute for Medical Research 10.1.6 European Bank for Induced Pluripotent Stem Cells (EBiSC) 10.2 Cell Sources for iPSC Banks 10.3 Reprogramming Methods in iPSC Banks 10.4 Ownership and Investments made in iPSC Banks 11. BIOMEDICAL APPLICATIONS OF IPSCs 11.1 iPSCs in Basic Research 11.2 Applications of iPSCs in Drug Discovery 11.3 Applications of iPSCs in Toxicology Studies 11.4 Applications of iPSCs in Disease Modeling 11.5 Applications of iPSCs in Cell-Based Therapies 11.6 Other Novel Applications of iPSCs 12. MARKET ANALYSIS 12.1 Global Market for iPSCs by Geography 12.2 Global Market for iPSCs by Technology 12.3 Global Market for iPSCs by Biomedical Application 12.4 Global Market for iPSCs by Derived Cell Type 12.5 Market Drivers 12.5.1 Current Drivers Impacting the iPSC Market Place 12.6 Market Restraints 13. COMPANY PROFILES For more information about this report visit https://www.researchandmarkets.com/r/pf57qx About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.